Earth Science Tech Business Summary

Earth Science Tech, Inc. (ETST) operates as a strategic holding company within the health and wellness sector, generating revenue through a vertically integrated model centered on pharmaceutical compounding and telemedicine. The company’s primary business segments include its licensed compounding pharmacies, RxCompoundStore.com and Mister Meds, which provide sterile and non-sterile medications, and its telemedicine platforms, Peaks Curative and Doconsultations.com, which facilitate patient-provider connections. Additional segments include healthcare facilities (Las Villas Health Care), real estate (Avenvi), and consumer products (MagneChef). ETST’s revenue is primarily transaction-based, derived from direct product sales and service fees, with a focus on capturing the full value chain from clinical consultation to prescription fulfillment. In the competitive landscape, ETST sits alongside BioStem Technologies, biote, Zevra Therapeutics, and Elite Pharmaceuticals, positioning itself as a diversified wellness aggregator that utilizes high-margin digital health platforms to drive scalable growth and superior operating leverage. The leadership team is anchored by CEO and Chairman Giorgio R. Saumat, an entrepreneur with over 20 years of experience in private equity and consulting who maintains a significant 42.19% ownership stake. He is supported by President and COO Mario G. Tabraue, an operations expert with a background in legal frameworks who was instrumental in the 2021 acquisition and subsequent scaling of the Peaks platform. Key executives include CFO Ernesto L. Flores, a finance veteran with a decade of experience, and CTO Chris Rose, who manages the company’s technological infrastructure. The Board of Directors features independent members Jeff P.H. Cazeau, an attorney and Audit Committee Chair, and Dr. Emiliano Curia. This team has recently spearheaded a major corporate restructuring, implementing governance reforms and cost-saving initiatives—including the voluntary rescission of executive employment agreements—to align leadership incentives with long-term shareholder value and prepare the company for institutional-ready public status by mid-2026.